PARMAR KUSH — SEC insider filings
SEC reporting owner CIK 1664281. 64 insider filings on record with FilingPulse; latest filed 2026-09-24.
Transaction summary — filings shown
Covers the 50 most recent of 64 filings on record, filed 2021-06-25 to 2026-09-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 11 legs across 9 filings — 12,275,057 shares, $79,546,008 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 59 legs across 21 filings — 5,452,488 shares, $59,198,456 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 61.
- Largest priced transaction: purchase of 487,333 shares @ $30.00 ($14,619,990) in CinCor Pharma, Inc., filed 2022-08-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 4 | — | 8 legs · 1,962,500 sh · $29,795,000 | — |
| CinCor Pharma, Inc. (CINC) | 10% owner | 3 | 4 legs · 1,070,000 sh · $25,520,000 | — | 8 |
| Skye Bioscience, Inc. (SKYE) | 10% owner | 7 | 2 legs · 5,656,074 sh · $16,526,031 | 25 legs · 1,055,553 sh · $2,995,503 | — |
| Rallybio Corp (RLYB) | Director | 11 | 1 leg · 615,384 sh · $7,999,992 | 7 legs · 560,000 sh · $6,735,500 | 13 |
| Camp4 Therapeutics Corp (CAMP) | 10% owner | 3 | 2 legs · 3,850,266 sh · $14,499,989 | — | 6 |
| Artiva Biotherapeutics, Inc. (ARTV) | 10% owner | 1 | 1 leg · 833,333 sh · $9,999,996 | — | 5 |
| Cabaletta Bio, Inc. (CABA) | 10% owner | 2 | — | 3 legs · 920,000 sh · $9,897,500 | — |
| Entrada Therapeutics, Inc. (TRDA) | Director | 12 | 1 leg · 250,000 sh · $5,000,000 | 14 legs · 623,729 sh · $4,715,151 | 16 |
| Vor Biopharma Inc. (VOR) | Director, 10% owner | 2 | — | 2 legs · 330,706 sh · $5,059,802 | 1 |
| Latigo Biotherapeutics, Inc. (LTGO) | 10% owner | 1 | — | — | 6 |
+2 more issuers among the filings shown — every filing appears in the table below.
Insider filings — PARMAR KUSH
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-24 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 27,612 @ $1.65 · Sale (S): 1,088 @ $1.65 · Sale (S): 114,851 @ $1.61 · Sale (S): 4,528 @ $1.61 | EDGAR |
| 2026-09-18 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-08-20 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-12 | 4 | Latigo Biotherapeutics, Inc. (LTGO) jointly with 5AM Ventures VI, L.P., 5AM Partners VI, LLC, 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, Schwab Andrew J. | Conversion (C): 4,975,543 · Conversion (C): 2,350,419 · Conversion (C): 3,152,305 (derivative) @ $0 · Conversion (C): 1,823,238 (derivative) @ $0 · Conversion (C): 866,018 (derivative) @ $0 · Conversion (C): 1,484,401 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 10,494 @ $7 · Sale (S): 52,317 @ $6.85 · Sale (S): 92,444 @ $7 | EDGAR |
| 2026-08-05 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Partners VII, LLC, 5AM Ventures VII, L.P. | Purchase (P): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 114,756 @ $6.93 · Sale (S): 1,718 @ $6.85 | EDGAR |
| 2026-06-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 200,000 @ $8.80 | EDGAR |
| 2025-09-15 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Partners VII, LLC, 5AM Ventures VII, L.P. | Purchase (P): 2,941,176 @ $1.53 | EDGAR |
| 2025-08-22 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-07-11 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 20,065 @ $7.50 · Sale (S): 6,935 @ $7.50 | EDGAR |
| 2025-07-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 55,735 @ $6.91 · Sale (S): 19,265 @ $6.91 · Sale (S): 18,578 @ $6.81 · Sale (S): 6,422 @ $6.81 · Sale (S): 18,578 @ $7.12 · Sale (S): 6,422 @ $7.12 | EDGAR |
| 2025-06-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P. | Conversion (C): 1,716,055 · Conversion (C): 302,770 · Purchase (P): 909,090 @ $11 · Conversion (C): 15,002,166 (derivative) · Conversion (C): 4,244,770 (derivative) · Conversion (C): 3,395,816 (derivative) | EDGAR |
| 2024-09-13 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-07-24 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., Schwab Andrew J. | Conversion (C): 1,058,284 · Other (J): 112,966 @ $10.20 · Other (J): 348,721 @ $10.20 · Purchase (P): 833,333 @ $12 · Conversion (C): 843,592 (derivative) · Conversion (C): 214,692 (derivative) | EDGAR |
| 2024-06-14 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Purchase (P): 450,000 @ $10 | EDGAR |
| 2024-02-16 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Sale (S): 688,358 @ $14.90 · Sale (S): 136,642 @ $14.90 | EDGAR |
| 2024-02-02 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Purchase (P): 5,206,074 @ $2.31 | EDGAR |
| 2024-02-02 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Sale (S): 417,187 @ $15 · Sale (S): 82,813 @ $15 | EDGAR |
| 2024-01-04 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 27,118 (derivative) @ $1.77 | EDGAR |
| 2023-09-28 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Sale (S): 164,789 @ $15 · Sale (S): 32,711 @ $15 | EDGAR |
| 2023-08-28 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Sale (S): 367,124 @ $16 · Sale (S): 72,876 @ $16 | EDGAR |
| 2023-06-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 15,490 (derivative) @ $0 | EDGAR |
| 2023-03-09 | 4 | Rallybio Corp (RLYB) | Sale (S): 100,000 @ $8.20 | EDGAR |
| 2023-02-28 | 4 | CinCor Pharma, Inc. (CINC) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I, L.P., Schwab Andrew J., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Opportunities I (GP), LLC | Code (U): 3,953,990 · Code (U): 487,333 · Code (U): 496,323 | EDGAR |
| 2023-01-05 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 10,344 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | Akouos, Inc. (AKUS) | Code (U): 3,153,333 · Code (U): 982,453 · Disposition to issuer (D): 16,000 (derivative) | EDGAR |
| 2022-08-17 | 4 | CinCor Pharma, Inc. (CINC) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P. | Purchase (P): 112,667 @ $30 · Purchase (P): 487,333 @ $30 | EDGAR |
| 2022-06-27 | 4 | Akouos, Inc. (AKUS) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Homology Medicines, Inc. (FIXX) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 16,911 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | Rallybio Corp (RLYB) | Sale (S): 99,671 @ $12.50 · Sale (S): 50,329 @ $12.50 | EDGAR |
| 2022-06-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 11,918 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 13,440 (derivative) @ $0 | EDGAR |
| 2022-05-25 | 4 | Rallybio Corp (RLYB) | Sale (S): 66,447 @ $13 · Sale (S): 33,553 @ $13 | EDGAR |
| 2022-02-10 | 4 | Rallybio Corp (RLYB) | Sale (S): 139,539 @ $13.05 · Sale (S): 70,461 @ $13.05 | EDGAR |
| 2022-01-13 | 4 | CinCor Pharma, Inc. (CINC) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Conversion (C): 3,683,823 · Conversion (C): 183,823 · Purchase (P): 157,500 @ $16 · Purchase (P): 312,500 @ $16 · Conversion (C): 9,999,999 (derivative) @ $0 · Conversion (C): 2,525,000 (derivative) @ $0 · +1 more | EDGAR |
| 2022-01-05 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 5,772 (derivative) @ $0 | EDGAR |
| 2021-11-18 | 4 | Vor Biopharma Inc. (VOR) | Sale (S): 238,870 @ $15.30 · Sale (S): 91,836 @ $15.30 | EDGAR |
| 2021-11-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Conversion (C): 318,616 · Conversion (C): 2,371,739 · Conversion (C): 564,217 · Conversion (C): 254,512 · Conversion (C): 318,140 · Purchase (P): 250,000 @ $20 · +5 more | EDGAR |
| 2021-11-03 | 4 | Cabaletta Bio, Inc. (CABA) jointly with 5AM Ventures V, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., 5AM Partners V, LLC, ROCKLAGE SCOTT M, Schwab Andrew J. | Sale (S): 258,456 @ $13 · Sale (S): 36,544 @ $13 | EDGAR |
| 2021-11-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 23,552 (derivative) @ $0 | EDGAR |
| 2021-09-09 | 4 | Cabaletta Bio, Inc. (CABA) jointly with 5AM Ventures V, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., 5AM Partners V, LLC, ROCKLAGE SCOTT M, Schwab Andrew J. | Sale (S): 625,000 @ $9.70 | EDGAR |
| 2021-08-04 | 4 | Rallybio Corp (RLYB) | Other (J): 2,784,626 · Other (J): 790,714 · Purchase (P): 615,384 @ $13 · Other (J): 1,795,946 (derivative) · Other (J): 8,742,654 (derivative) · Other (J): 7,192,795 (derivative) · +2 more | EDGAR |
| 2021-06-25 | 4 | Akouos, Inc. (AKUS) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1664281 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs